© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
July 01, 2021
Early study results indicate that STADA Arzneimittel and Xbrane Biopharma’s ranibizumab biosimilar is as safe and effective as the reference product, suggesting regulatory approval may be on the horizon.
May 04, 2021
Biosimilar companies partnered with other companies and saw earnings increases, while reference product corporations faced sales erosion from biosimilar competition.
April 12, 2021
To overcome provider and patient preferences for brand originators, there has to be more of an incentive to use biosimilars, explains Nedzad Pojskic, PhD, MSc, Green Shield Canada.
April 01, 2021
The month of March brought intense debate and legislative action over biosimilar policies.